Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01020747 · ClinicalTrials.gov registry record · Phase 1
Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)
A Phase 1 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT01020747: Completed Phase 1 study, sponsored by Massachusetts General Hospital.
NCT01020747 is a Phase 1 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 20 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01020747, a Phase 1 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected into the vocal folds. Patients who enroll in the protocol will be injected with bevacizumab in one vocal fold that represents the more diseased of the two folds. A sham injection with saline will be administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection. The investigator will also treat lesions by laser photoangiolysis of both vocal folds using the 532 nm potassium-titanyl-phosphate (KTP) laser.
Interventions
- DRUG Saline
- DRUG Avastin® (bevacizumab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01020747
The ClinicalTrials.gov registry entry for NCT01020747 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Saline is the first listed.
NCT01020747 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01020747 about?
NCT01020747 is a clinical study titled "Bevacizumab for Treatment of Recurrent Respiratory Papillomatosis (RRP)". This phase I single center open labeled study is planned to assess the safety and tolerability of bevacizumab for treating patients with bilateral Recurrent Respiratory Papillomatosis (RRP). Approximately 20 patients will receive bevacizumab directly injected into the vocal folds. Patients who enrol...
What is the current status of trial NCT01020747?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2009-11. Estimated completion is 2011-03.
What interventions are being tested in trial NCT01020747?
The interventions under investigation include: Saline (DRUG), Avastin® (bevacizumab) (DRUG).
Who is sponsoring clinical trial NCT01020747?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.